BEIJING - China's central government is set to launch sweeping reforms of the country's health system, with the ultimate goal of providing universal health care by the year 2020
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
